Yu Lifeng, Zhao Lin, Wu Huizhe, Zhao Haishan, Yu Zhaojin, He Miao, Jin Feng, Wei Minjie
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China.
Department of Breast Surgery, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Oncol Lett. 2019 Feb;17(2):1921-1933. doi: 10.3892/ol.2018.9799. Epub 2018 Dec 6.
Moesin, a cytoskeletal protein belonging to the ezrin-radixin-moesin family serves important roles in cell motility, invasion and metastasis. Moesin has been demonstrated to be of prognostic significance in tumor progression, due to its role in the metastatic process; however, its role in breast cancer is not well characterized. In the present study, the moesin expression was determined using immunohistochemistry in 404 and 46 patients with breast cancer and fibroadenoma, respectively, and the associations between moesin expression and the clinical parameters and prognostic values were analyzed. The positive rate of moesin protein expression was 47.8% (193/404) in breast cancer tissues, which was significantly higher than in fibroadenoma tissues (15.2%, 14/46). Overexpression of moesin was significantly associated with advanced clinical stage (P=0.002), positive lymph node metastasis (P<0.0001), and estrogen receptor (ER; P=0.008) and progesterone receptor (P=0.026) status. Patients with high moesin expression had significantly lower recurrence-free survival time, compared with patient with low moesin expression. Notably, overexpression of moesin was significantly associated with poor prognosis in patients with ER-positive breast cancer, and in patients treated with tamoxifen. Using a Cox proportional hazard regression model, further analysis was conducted, which demonstrated that moesin overexpression was a predictive prognostic factor for reduced overall survival time in patients with ER-positive breast cancer, and in patients treated with tamoxifen. These results indicated that moesin may be a potential marker for poor prognosis in patients with ER-positive breast cancer treated with tamoxifen. In conclusion, moesin serves an important role in the progression of breast cancer, and may be a valuable marker of breast cancer prognosis.
膜突蛋白是一种属于埃兹蛋白-根蛋白-膜突蛋白家族的细胞骨架蛋白，在细胞运动、侵袭和转移中发挥重要作用。由于膜突蛋白在转移过程中的作用，它已被证明在肿瘤进展中具有预后意义；然而，其在乳腺癌中的作用尚未得到充分表征。在本研究中，分别使用免疫组织化学方法检测了404例乳腺癌患者和46例纤维腺瘤患者的膜突蛋白表达，并分析了膜突蛋白表达与临床参数及预后价值之间的关联。膜突蛋白在乳腺癌组织中的阳性表达率为47.8%（193/404），显著高于纤维腺瘤组织（15.2%，14/46）。膜突蛋白的过表达与临床晚期（P=0.002）、阳性淋巴结转移（P<0.0001）以及雌激素受体（ER；P=0.008）和孕激素受体（P=0.026）状态显著相关。与膜突蛋白低表达的患者相比，膜突蛋白高表达的患者无复发生存时间显著缩短。值得注意的是，膜突蛋白的过表达与ER阳性乳腺癌患者以及接受他莫昔芬治疗的患者的不良预后显著相关。使用Cox比例风险回归模型进行进一步分析，结果表明膜突蛋白过表达是ER阳性乳腺癌患者以及接受他莫昔芬治疗的患者总生存时间缩短的预测预后因素。这些结果表明，膜突蛋白可能是接受他莫昔芬治疗的ER阳性乳腺癌患者预后不良的潜在标志物。总之，膜突蛋白在乳腺癌进展中起重要作用，可能是乳腺癌预后的一个有价值的标志物。
